FDA
approval
· 2011-05-02
FDA Approved: TRADJENTA — Original Application (Boehringer Ingelheim Pharmaceuticals, Inc.)
Summary
FDA approved Tradjenta (linagliptin) as a new treatment for type 2 diabetes, representing the original approval of this DPP-4 inhibitor.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
ORIG AP for TRADJENTA (LINAGLIPTIN)